NMRA-898 is structurally distinct from NMRA-861 and is the second M4 PAM in Neumora’s M4 franchise; both programs have potential best-in-class pharmacology No convulsions observed in pre-clinical ...

Follicle-stimulating hormone (FSH), a glycoprotein secreted by gonadotroph cells of the anterior pituitary, is classically ...

The ODD programme incentivises the development of medicines for conditions affecting fewer than 200,000 individuals in the US ...

The U.S. Food and Drug Administration (FDA) has granted orphan drug designation to DPTX3186, an investigational therapy being ...

Aldeyra has since resubmitted its application, buffing it up with a “single clinical trial that achieved the primary endpoint ...

IND opening marks culmination of partnership between Dewpoint and Evotec, advancing a de novo development candidate through ...

First orphan designation ever granted to a condensate-modulating tBuilds on recent IND opening for DPTX3186, a first-in-class oral condensate modulator targeting the Wnt/β-catenin pathwayProvides key ...

US biotech Dewpoint Therapeutics has announced that the US Food and Drug Administration (FDA) has granted Orphan Drug ...

Topline results were announced from a phase 3 trial evaluating BNC210 in patients with social anxiety disorder.

CAMBRIDGE, Mass.--(BUSINESS WIRE)--HyperLight, creator of the TFLN Chiplet™ platform, today announced the launch of its groundbreaking 110 GHz Low Vπ Intensity Modulator, featuring industry-standard ...